Navigation Links
Future for clean energy lies in 'big bang' of evolution
Date:8/25/2008

Amid mounting agreement that future clean, "carbon-neutral", energy will rely on efficient conversion of the sun's light energy into fuels and electric power, attention is focusing on one of the most ancient groups of organism, the cyanobacteria. Dramatic progress has been made over the last decade understanding the fundamental reaction of photosynthesis that evolved in cyanobacteria 3.7 billion years ago, which for the first time used water molecules as a source of electrons to transport energy derived from sunlight, while converting carbon dioxide into oxygen. The light harvesting systems gave the bacteria their blue ("cyano") colour, and paved the way for plants to evolve by "kidnapping" bacteria to provide their photosynthetic engines, and for animals by liberating oxygen for them to breathe, by splitting water molecules. For humans now there is the tantalising possibility of tweaking the photosynthetic reactions of cyanobacteria to produce fuels we want such as hydrogen, alcohols or even hydrocarbons, rather than carbohydrates.

Progress at the research level has been rapid, boosting prospects of harnessing photosynthesis not just for energy but also for manufacturing valuable compounds for the chemical and biotechnology industries. Such research is running on two tracks, one aimed at genetically engineering real plants and cyanobacteria to yield the products we want, and the other to mimic their processes in artificial photosynthetic systems built with human-made components. Both approaches hold great promise and will be pursued in parallel, as was discussed at a recent workshop focusing on the photosynthetic reaction centres of cyanobacteria, organised by the European Science Foundation (ESF).

A key point noted by Eva Mari Aro, the vice-chair of the ESF conference, was that there is now universal agreement over the ability of photosynthesis to provide large amounts of clean energy in future. While the sustainable options currently purs
'/>"/>

Contact: Eva-Mari Aro
evaaro@utu.fi
358-233-35931
European Science Foundation
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. New book tutors future presidents and public on science behind the headlines
2. Genetic data promises new future for kiwi fruit
3. A bees future as queen or worker may rest with parasitic fly
4. Training future scientists at the Ecological Society of Americas 93rd Annual Meeting
5. Study: Future snowmelt in West twice as early as expected; threatens ecosystems and water reserves
6. Algae from the ocean a sustainable energy source of the future
7. The AGA Foundation invests in gastroenterologys future
8. Securing the future of Europes biological data resources
9. U-M scientists remove thousands of aspens to glimpse forests future
10. Crystal (eye) ball: Study says visual system equipped with future seeing powers
11. Emissions irrelevant to future climate change?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... biologists, led by Clemson University associate professor Andrew S. ... will pave the way for novel anti-fouling paint for ... and industrial applications. , The team,s findings, published in ... larval stage of barnacles that attaches to a wide ... material that acts as an underwater heavy-duty adhesive. , ...
(Date:7/30/2014)... Portland Press Limited today announced an across-the-board increase ... , The 2013 InCites Journal Citation Reports (Thomson ... Biochemical Journal , Essays in Biochemistry ... Bioscience Reports all received increases in their ... Biochemical Society and published by Portland Press Limited. ...
(Date:7/30/2014)... A professor from Wayne State University,s College of ... National Science Foundation for the project, "Nanoparticle-directed synthesis ... National Science Foundation, nanotechnology is the creation and ... novel properties and functions. A major bottleneck in ... methods that connect different functional materials into one ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2Across-the-board Impact Factor increases for Portland Press Limited 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... have created the first three-dimensional living tissue model, complete ... therapeutics to combat brain tumors. The 3-D model gives ... tissue cultures. The researchers created a glioma, or ... surrounds it. In a series of experiments, the team ...
... have succeeded in changing the genetic material of cancer ... in nanosurgery opens the door to new medical applications, ... A light scalpel to treat cancerous cells, The ... team uses a femtosecond laser (a laser with ultra-short ...
... Resolving the world,s major challenges whether climate change, ... scarcity requires a sweeping shift in our approach ... leading scientists told European policy makers today during ... and Societal Challenges for our Unstable Earth" (RESCUE). ...
Cached Biology News:Researchers make living model of brain tumor 2Europe needs a 'RESCUE' revolution 2Europe needs a 'RESCUE' revolution 3
(Date:7/30/2014)... , July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... the Day 180 List of Outstanding Issues (LOI) from ... Human Use (CHMP) for the NB32 Marketing Authorization Application ... is an investigational drug candidate being evaluated for weight ... Day 120 time point were adequately addressed by the ...
(Date:7/30/2014)...  AtheroNova Inc. (OTCBB: AHRO), a biotech company ... to safely regress atherosclerotic plaque and improve lipid ... CardioNova, has accomplished first dosing of subjects for ... compound, AHRO-001.  This Phase 1b trial will be ... trial completed in February 2014, in which patients ...
(Date:7/30/2014)... July 30, 2014 Vala Sciences ... U.S. Environmental Protection Agency (EPA). This new contract ... toxicity models, including tests designed to assess the ... the formation of connections between neurons (synapses), which ... and synapse formation by environmental pollutants likely contributes ...
(Date:7/29/2014)... July 30, 2014 SoundConnect ... collaboration company, is proud to announce the strategic ... positions in their Boston, Charleston and Atlanta offices. ... the increased demand for hosted solutions, collaboration and ... and reduce cost. , SoundConnect was founded in ...
Breaking Biology Technology:Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3SoundConnect Organization and Culture is Evolving 2
... July 14 Bio-Optronics, Inc., a leader in healthcare workflow ... software solution that can simultaneously handle the most intricate scheduling ... staff schedules. , , Physician ... , Bio-Optronics President & CEO, ...
... , HALIFAX, NS, July 14 /PRNewswire/ - ImmunoVaccine ... entered into an agreement to exclusively license seven ... company. These proprietary antigens specifically target breast, ovarian ... antigens with its DepoVax(TM) delivery platform to develop ...
... , , TAMPA, Fla., July ... on the research and development of cancer immunotherapies, announces that the ... its dendritic cell therapy. , , ... I/II clinical trial testing the safety and efficacy of its immunotherapy ...
Cached Biology Technology:NEW Momentum(TM) Physician and Staff Scheduling Software for Imaging Centers, OB/GYN, and Other Specialty Practices Improves Productivity and Equity in Scheduling 2ImmunoVaccine Technologies Licenses Immunotope's Breast, Ovarian and Prostate Cancer Antigens 2Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial 2Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial 3